Nanotechnology: A new way to fight cancer?

Transcription

1 HKU Ecom-Icomp Expert Address Series 2015 Nanotechnology: A new way to fight cancer? Professor Amy Shuen and CEO, Nanoforma November 11, 2015 Nanoforma contact: amy@nanoforma.com 1

2 A Fantastic Voyage Nanoforma Proprietary 2

3 A Simple Approach Shrink the vehicle Guide the carrier Destroy the disease Nanoforma Proprietary 3

4 50 years later Shrink the vehicle Guide the carrier Destroy the disease Nanoforma Proprietary 4

5 Problem: Chemo-drugs are not reaching tumors 98% off-target Cost of New Drug 2015 $2.6 BILLION Nanoforma contact: 5

6 Solution: Transformative Nano-Drug Tumor Delivery Tumor triggered release 100x-500x Tumor Uptake FDA-approved Drug Molecules Nanocarrier With Specific 3D Shape and Exact Dimensions Imaging Tracer Safer updosing & reduced offtarget effects Nanoforma contact: 6

7 Game-changer 100x-500x Tumor Uptake Nanoforma Proprietary 7

8 Protein Bio-Synthesis & Drug Conjugation Key Research Breakthroughs Computational Nano-Physics Molecular Imaging & Translational Science Nanoforma Proprietary 8

9 Game-changing nano-drug delivery Glioblastoma Brain Tumor Liver Tumor Pancreatic Tumor Supercomputer Nano-Physics Median Survival 13.5 months Limited treatment options Median Survival 6 months 15k U.S Deaths per year 3 rd leading cause of cancer deaths worldwide 4 th leading cause of cancer deaths Nanoforma contact: amy@nanoforma.com 9

10 Next Steps: Funding for FDA Approval Process Nanoforma contact: 10

11 Score: 500 Successful Life Sciences Startups! Nanoforma contact: 11

12 Life Sciences Lean Launchpad Program Dr. Hobart Harris, UCSF Chief of Surgery and Lean Launchpad Life Sciences Startup Founder Nanoforma contact: 12

13 #24_The Nanoforma Lean Launchpad Team Amy Shuen Team Lead Pratixa Joshi, Nanotech Expert PJ Buske Science Expert Rodrigo Vilela Business Dev. Jon Hong Strategy/Finance 71 In-person / webcon: 59 Phone: 12 UCSF-Berkeley-Stanford Founding Team TECHNOLOGY In Silico Nano- Physics Tumor Engineering Optimization TECHNOLOGY In Vitro Synthesis of Protein Nano- Carriers, Characterize & Drug-Load BUSINESS Operations, Business Model, Financials, IP Strategy, Partnerships CLINICAL TRANSLATION Preclinical to IND Development, Regulatory to PH1 Human Trials Prof Eric Shaqfeh Prof Matthew Francis Former UCB Prof Amy Shuen Dr. Mitchel Berger Chair, Chemical Engineering Associate Dean, Chemistry CEO, Nanoforma Chair, Neurological Surgery Director, BTRC; 2012 President AANS Nanoforma contact: amy@nanoforma.com 13

14 First Business Canvas: Original Idea Sell to Big Pharma! IP Licensing revenues Nanoforma contact: 14

15 The question you should be asking is: What We Heard What would you partner with us on: A glioblastoma drug, a nanocarrier delivery platform, or the computational model? - Neena Kadoba, QB3 Both Genentech and Amgen would ditch their current Antibody Drug Conjugate platforms if they had an alternative tumor targeting option. - Joeren Grasman, Genentech Business Development Good time to go for funding--all the Pharmas are disenchanted with mabs and looking for the next big breakthrough. -Devin Huyhn, GE Healthcare Nanoforma contact: amy@nanoforma.com 15

16 Co-development Partners vs. Licensing Customers 3-5 years Co-Development...Licensing Preclinical Phase 1 Phase 2 Commercial Innovation VC Funds (preclinical/ early stage) Business Development (later stage) Nanoforma contact: amy@nanoforma.com 16

17 Week 5 Business Model Canvas Co-development Drug Delivery Partnerships Now Licensing Customers Later Nanoforma contact: amy@nanoforma.com 17

18 What we heard Sanofi has a group that co-creates companies, You have to come in knowing getting DebioPharm how involved a company at is a multi-billion very early stage dollar and Swiss invests specialty like Merck can use it. Show alongside us pharma what options venture company acapitalists that looks with to a partner focus on and invest on partnership with you will open hard-to-treat novel up for complex us. tumors. cancer drugs. -Oscar Giaverini -Sylviane -Maria Cases Chiam Associate Director, Evaluation Director Business & Analysis, of External Development, Merck Innovation, DebioPharm Sanofi Potential Big Pharma Partner #1 Merck s Temodar off patent in 2013 Potential Big Pharma Partner #2 Orphan Diseases International Regulations Specialty Pharma Partner #3 Smaller Nimble Private + Complex Mfg Skills Nanoforma contact: amy@nanoforma.com 18

19 Final Business Model Canvas MVP Nano-drug Tumor Delivery Platform + NCL + Scale-up = Green light Go Ahead Nanoforma contact: amy@nanoforma.com 19

20 What we heard The biologics cost $250/dose versus 25 for small No molecule it is not a pills. biologic. A non-biologic It is a nonbiologic targeting complex tumors would drug. have NCL unique is free drug platform for advantages. Jeroen Grasman Marina Dobrovolskaia, Ph.D., Co-Director Senior Director of Finance - Global Biologics Nanotechnology Characterization Lab Manufacturing at Genentech Nanoforma contact: amy@nanoforma.com 20

21 MVP: Nano-drug delivery platform Amount of Drug (# of drug molecules) delivered to Brain Tumor vs. Free drug Size Size distribution Topology Molecular Weight Aggregation Purity Chemical Composition Surface Characteristics Functionality Stability Solubility Zeta Potential Drug-loaded Nano-carrier 3D Particle Geometry Nano-carrier vs. Free drug delivery Illustrative diagrams and parameters--not actual shapes or data results Tumor extravasation measurements 21 Nanoforma contact: 21

22 Go No go slide Contact Amy Shuen, Nanoforma CEO Nanoforma.com Nanoforma contact: amy@nanoforma.com 22